By NOAM N. LEVEY and JENNIFER HABERKORN In a much-anticipated piece of political theater, seven leading pharmaceutical executives appeared before a powerful Senate committee Tuesday for a grilling from lawmakers who pledged a historic bipartisan effort to rein in skyrocketing prescription drug prices. But even as drug prices have emerged as one of the few areas of common […]
The Seven Deadly Sins of the Prescription Drug Affordability Market
By: John Rother The problem of unaffordable prescription drug prices is not a simple on, nor is there a single policy that addresses the full range of issues. We need to fix the current broken system to make drugs more affordable while maintaining incentives to discover important new cures. There are seven “deadly sins” that now characterize […]
WSJ: Would Drug Price Controls Kill Innovation?
The original letter to the editor was published on January 15, 2018 and can be found here. The article in which the letter responds to can be found here. By John Rother The U.S. is alone among developed nations in failing to assure more affordable medications for its citizens. Medicare trustees have an obligation to act prudently to obtain fair prices for beneficiaries. Recent research has […]
Op-Ed: The Necessity Of Exploiting Pricing Power in a Post-Consolidated Health Care World
By John Rother & David Introcaso Originally posted on Morning Consult. You can read the original op-ed here. Americans are forced to spend over $1 trillion annually on health care services that do not improve their health. What causes this is not the amount of health care services we consume. Compared to similar countries, the […]
Now is the Time to Lower Prescription Drug Prices
By John RotherBlog post from January 7, 2018 There were two big stories from the pharmaceutical industry this week, both reported by the Wall Street Journal: 1) Bristol-Myers Squibb intends to acquire Celgene in a $74 billion dollar deal; and 2) drug manufacturers have already hiked prices for hundreds of medicines for 2019. Both stories […]